Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zimmer Biomet Holdings's EV-to-EBIT or its related term are showing as below:
XSWX:ZBH'
s EV-to-EBIT Range Over the Past 10 Years
Min: -6035.55 Med: 36.57 Max: 1850.86
Current: 20.36
During the past 13 years, the highest EV-to-EBIT of Zimmer Biomet Holdings was 1850.86. The lowest was -6035.55. And the median was 36.57.
XSWX:ZBH's EV-to-EBIT is ranked worse than 55.48% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.24
vs XSWX:ZBH: 20.36
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zimmer Biomet Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was CHF19,092 Mil.
Zimmer Biomet Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF956 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Zimmer Biomet Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's EV-to-EBIT falls into.
Zimmer Biomet Holdings's current Enterprise Value is CHF19,869 Mil.
Zimmer Biomet Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF956 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings (XSWX:ZBH) has a EV-to-EBIT of 20.78 as of Jul. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zimmer Biomet Holdings and its competitors. This is 43% below median its historical median of 36.57. According to the industry distribution chart, Zimmer Biomet Holdings ranks #258 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 55.5%.
Is Zimmer Biomet Holdings' EV-to-EBIT too high?
Zimmer Biomet Holdings' current EV-to-EBIT of 20.78 is 43% below median its 10-year median of 36.57. The Medical Devices & Instruments industry median EV-to-EBIT is 18.24. Zimmer Biomet Holdings' value of 20.78 is 13.9% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #258 out of 465 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' EV-to-EBIT compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #258 out of 465 companies for EV-to-EBIT. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median EV-to-EBIT is 18.24. Zimmer Biomet Holdings' value of 20.78 is 13.9% above this benchmark. While the company's 10-year median is 36.57 vs. the industry median of 18.24, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.24, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current EV-to-EBIT of 20.78 is 13.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current EV-to-EBIT is 20.78, which is 43% below median its own 10-year median of 36.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current EV-to-EBIT of 20.78. The stock's GF Value™ is CHF102.24, compared to a current price of CHF72.50 — trading 29.1% below its estimated fair value. The current EV-to-EBIT is 20.78, which is 43% below median its 10-year median of 36.57 and 13.9% above the Medical Devices & Instruments industry median of 18.24. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current EV-to-EBIT is 20.78 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF72.50 is trading 29.1% below its estimated GF Value™ of CHF102.24.
Key valuation signals for XSWX:ZBH:
EV-to-EBIT: 20.78 (43% below median its 10-year median of 36.57)
GF Value™: CHF102.24 vs. price of CHF72.50 (29.1% below fair value)
Industry Position: 13.9% above the Medical Devices & Instruments median (#258 of 465)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score
Get the complete analysis for XSWX:ZBH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
